Accelerate Diagnostics Appoints Chief Commercial Officer
TUCSON, Ariz., July 1, 2013
TUCSON, Ariz., July 1, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc.
(NASDAQ: AXDX), today announced that it has appointed Pete Bantock to the
position of Chief Commercial Officer, effective today.
Most recently Pete was Sr. Vice President and General Manager of Ventana
Medical Systems' North American Commercial Operations. Previously, Pete was
the General Manager of Spring Bioscience, a division of Ventana. Prior to
Spring, Pete held various sales and marketing positions at Ventana including
director of marketing and head of corporate accounts.
Pete began his healthcare career at Abbott Labs where he was manager of South
African commercial operations for the Diagnostics Division, among other roles.
"We are delighted to welcome Pete to our leadership team," saidLawrence
Mehren, CEO of Accelerate Diagnostics. "Pete's two decades of commercial
experience in diagnostics and healthcare as well as his general management
expertise will be a tremendous benefit as we aggressively pursue our
"I am privileged to be joining such a dynamic and talented team," said
Bantock. "Accelerate's differentiated technology promises to make a dramatic
impact on patient care by rapidly providing physicians and microbiologists
with critical information to better manage infectious disease."
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in-vitro diagnostics company
focused on developing and commercializing innovative systems for the rapid
identification and antibiotic susceptibility testing of infectious pathogens.
The Company's revolutionary BACcel™ platform utilizes a proprietary
culture-free process with both genomic and phenotypic detection technologies
that significantly decreases time to result while achieving high sensitivity
and specificity.In addition to the BACcel system development pipeline, the
Company also owns and licenses its proprietary OptiChem™ surface coatings
technology, which has numerous applications for binding in bio-analytical
systems, such as microarrays. For more information, visit:
This press release contains words such as "expects," "shall," "will,"
"believes" and other similar expressions that are intended to identify
forward-looking statements within the meaning of the Safe Harbor Provisions of
the Private Securities Litigation Reform Act of 1995. Such statements in this
announcement are made based on the Company's current beliefs, known events and
circumstances at the time of publication and, as such, are subject in the
future to unforeseen risks and uncertainties that could cause the Company's
results of operations, performance and achievements to differ materially from
current expectations expressed in, or implied by, these forward-looking
statements. For a full discussion of the Company's risks and uncertainties,
which could cause actual results to differ from those contained in the
forward-looking statements, see "Risk Factors" in Item 1A in the Company's
Transition Report on Form 10-KT, filed with the SEC on March 20, 2013. In
addition, the Company's forward-looking statements could be affected by
general industry and market conditions and growth rates. Except as required
by federal securities laws, the Company undertakes no obligation to update or
revise these forward-looking statements to reflect new events, uncertainties
or other contingencies.
SOURCE Accelerate Diagnostics, Inc.
Contact: Samantha McCue, 730-841-1081, email@example.com
Press spacebar to pause and continue. Press esc to stop.